K K Venkatesh1, C W Chiang2, W C Castillo3, A N Battarbee4, M Donneyong5, L M Harper6, M Costantine1, G Saade7, E F Werner8, K A Boggess9, M B Landon1. 1. Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, USA. 2. Department of Bioinformatics, The Ohio State University, Columbus, OH, USA. 3. Department of Pharmaceutical Health Services Research, University of Maryland Baltimore, Baltimore, MD, USA. 4. Department of Obstetrics and Gynecology, University of Alabama, Birmingham, AB, USA. 5. College of Pharmacy, The Ohio State University, Columbus, OH, USA. 6. Department of Women's Health, University of Texas, Dell Medical School, Austin, TX, USA. 7. Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA. 8. Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI, USA. 9. Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA.
Abstract
OBJECTIVE: To define patterns of prescription and factors associated with choice of pharmacotherapy for gestational diabetes mellitus (GDM), namely metformin, glyburide and insulin, during a period of evolving professional guidelines. DESING: Cross-sectional study. SETTING: US commercial insurance beneficiaries from Market-Scan (late 2015 to 2018). STUDY DESIGN: We included women with GDM, singleton gestations, 15-51 years of age on pharmacotherapy. The exposure was pharmacy claims for metformin, glyburide and insulin. MAIN OUTCOMES: Pharmacotherapy for GDM with either oral agent, metformin or glyburide, compared with insulin as the reference, and secondarily, consequent treatment modification (addition and/or change) to metformin, glyburide or insulin. RESULTS: Among 37 762 women with GDM, we analysed data from 10 407 (28%) with pharmacotherapy, 21% with metformin (n = 2147), 48% with glyburide (n = 4984) and 31% with insulin (n = 3276). From late 2015 to 2018, metformin use increased from 17 to 29%, as did insulin use from 26 to 44%, whereas glyburide use decreased from 58 to 27%. By 2018, insulin was the most common pharmacotherapy for GDM; metformin was more likely to be prescribed by 9% compared with late 2015/16, but glyburide was less likely by 45%. Treatment modification occurred in 20% of women prescribed metformin compared with 2% with insulin and 8% with glyburide. CONCLUSIONS: Insulin followed by metformin has replaced glyburide as the most common pharmacotherapy for GDM among a privately insured US population during a time of evolving professional guidelines. Further evaluation of the relative effectiveness and safety of metformin compared with insulin is needed. TWEETABLE ABSTRACT: Insulin followed by metformin has replaced glyburide as the most common pharmacotherapy for gestational diabetes mellitus in the USA.
OBJECTIVE: To define patterns of prescription and factors associated with choice of pharmacotherapy for gestational diabetes mellitus (GDM), namely metformin, glyburide and insulin, during a period of evolving professional guidelines. DESING: Cross-sectional study. SETTING: US commercial insurance beneficiaries from Market-Scan (late 2015 to 2018). STUDY DESIGN: We included women with GDM, singleton gestations, 15-51 years of age on pharmacotherapy. The exposure was pharmacy claims for metformin, glyburide and insulin. MAIN OUTCOMES: Pharmacotherapy for GDM with either oral agent, metformin or glyburide, compared with insulin as the reference, and secondarily, consequent treatment modification (addition and/or change) to metformin, glyburide or insulin. RESULTS: Among 37 762 women with GDM, we analysed data from 10 407 (28%) with pharmacotherapy, 21% with metformin (n = 2147), 48% with glyburide (n = 4984) and 31% with insulin (n = 3276). From late 2015 to 2018, metformin use increased from 17 to 29%, as did insulin use from 26 to 44%, whereas glyburide use decreased from 58 to 27%. By 2018, insulin was the most common pharmacotherapy for GDM; metformin was more likely to be prescribed by 9% compared with late 2015/16, but glyburide was less likely by 45%. Treatment modification occurred in 20% of women prescribed metformin compared with 2% with insulin and 8% with glyburide. CONCLUSIONS: Insulin followed by metformin has replaced glyburide as the most common pharmacotherapy for GDM among a privately insured US population during a time of evolving professional guidelines. Further evaluation of the relative effectiveness and safety of metformin compared with insulin is needed. TWEETABLE ABSTRACT: Insulin followed by metformin has replaced glyburide as the most common pharmacotherapy for gestational diabetes mellitus in the USA.
Authors: Wendy Camelo Castillo; Kim Boggess; Til Stürmer; M Alan Brookhart; Daniel K Benjamin; Michele Jonsson Funk Journal: JAMA Pediatr Date: 2015-05 Impact factor: 16.193
Authors: Diane Farrar; Mark Simmonds; Maria Bryant; Trevor A Sheldon; Derek Tuffnell; Su Golder; Debbie A Lawlor Journal: BMJ Open Date: 2017-06-24 Impact factor: 2.692
Authors: Janet A Rowan; Elaine C Rush; Lindsay D Plank; Jun Lu; Victor Obolonkin; Suzette Coat; William M Hague Journal: BMJ Open Diabetes Res Care Date: 2018-04-13
Authors: Carolyn E Cesta; Jacqueline M Cohen; Laura Pazzagli; Brian T Bateman; Gabriella Bröms; Kristjana Einarsdóttir; Kari Furu; Alys Havard; Anna Heino; Sonia Hernandez-Diaz; Krista F Huybrechts; Øystein Karlstad; Helle Kieler; Jiong Li; Maarit K Leinonen; Hanne L Gulseth; Duong Tran; Yongfu Yu; Helga Zoega; Ingvild Odsbu Journal: BMJ Open Diabetes Res Care Date: 2019-11-02
Authors: Kartik K Venkatesh; Courtney D Lynch; Camille E Powe; Maged M Costantine; Stephen F Thung; Steven G Gabbe; William A Grobman; Mark B Landon Journal: JAMA Date: 2022-04-12 Impact factor: 157.335